Correlation of apoptosis genes of p53，bcl-2 and bax in tissue of prostate
FANG Zhi-Qi, TUN Gang, WANG He-Ban, CHEN Xiao-Yu
Chinese Journal of Clinical Anatomy ›› 2013, Vol. 31 ›› Issue (5) : 560-563.
Correlation of apoptosis genes of p53，bcl-2 and bax in tissue of prostate
Objective To investigate clinical significance and expression between apoptosis and the expression of the related genes of p53，bcl-2 and bax in prostate cancer (PCa). Methods The expression of bcl-2, bax and p53 protein and apoptosis cells were detected by immunohistochemical S-P method respectively in tissues of 36 cases of PCa, 20 BPH and 11 NP. Results ① It showed that bcl-2 expression in Pca was significantly higher than that in NP and BPH (P<0.05), and there was no significant difference between PCa and BPH(P>0.05). p53 expression in PCa was significantly higher than that in BPH and NP (P<0.01), and there was no significant difference between BPH and NP(P>0.05). ② In the tissue of Pca， p53 and bcl-2 expression was positively correlated with pathological grade, as PCa increased in grades (P<0.05, P<0.01).It showed that expression levels of bcl-2 and p53 protein in PCa tissues increased with the progression of pathological grade. Bax positive expressing rate difference had no significance in PCa, BPH and NP. ③The expression of p53 was frequently detected in shorter-than-5-year survival group, than it was in longer-than-5-year survival group(P<0.05). That of bcl-2 expression was not related to survival period(P>0.05). Conclusion The over-expression of apoptosis-related genes: bcl-2，bax and p53 might be related to the carcinogenesis，progression pathological grade and prognosis of prostate carcinoma
Prostatic neoplasmas / Genes / bcl-2 / Immunohistochemistry / p53 / Bax
[1] Stephan C, Rittenhouse H, Cammann H, et al. New markers and multivariate models for prostate cancer detection.
[J]Anticancer Res,2009,29(7):2589-2600.
[2] Gleason DF, Melinger GT. The VACURG prediction of prognosis for prostatic adenocarcinoma by combined histological and clinical staging
[J]. J Urol, 1999,111(4):58-64.
[3] Secchiero P,Zerbinsti C, di Iasio MG, et al.Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells
[J]. Curr Drug Metab, 2007,8(4):395-403.
[4] Wang TT, Xu C, Liu SL, et al. Clinicopathology, immunophenotype, T cell receptor gene rearrangement, Epstein-Barr virus status and p53 gene mutation of cutaneous extranodal NK/T-cell lymphoma, nasal-type
[J].Chin Med J (Engl), 2013,126(7):1281-1287.
[5] Sohn S, Jung T, Kim D, et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse largeB2-cell lymphoma
[J]. Am J He matol, 2003, 73 (2) :101-103.
[6] 王晓波, 梅骅.前列腺癌中p53基因突变及蛋白表达的研究
[J].中华泌尿外科杂志,1994,15(5):333-336.
[7] KoS C, Gotoh A, Thalmann GN, et al. Moleculsar therapy with re-combinant p53 adenovirus in an androgen-independent metastatic human prostate cancer model
[J]. Hum Gene Ther 1996,7(14):1683-1687.
[8] Andersen JL, Jason L, Zimmerman ES, et al. HIV-1 v-induced apoptosis is cell cycle dependent and requires bax but not ant
[J]. J Pathog, 2006, 2(12): 127-132.
[9] Montironi R. Prognostic factors in prostate cancer
[J]. BMJ, 2001, 322(7283): 378-379.
[10]Taghavi N, Biramijamal F, Sotoudeh M, et al.p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma
[J]. BMC Cancer, 2010,10(1):138-140.
[11] Mearini E, Antognelli C, Del Buono C, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer
[J]. Biomarkers, 2009, 14(4): 235- 243.
[12] 赵小东,赵立明,王永翔, 等. CD44s和CD15在前列腺癌组织中的表达及其意义
[J].国际泌尿外科杂志, 2010, 30(6):123-126.
[13] 方德全, 余宏铸, 许业传, 等. 前列腺素E1对梗阻性黄疸大鼠肝细胞凋亡及相关基因Bax/Bcl-2表达的影响
[J]. 安徽医科大学学报, 2011, 46(8):742-746.
/
| 〈 |
|
〉 |
